Eravacycline dihydrochloride is primarily used as an antibiotic to treat complicated intra-abdominal infections (cIAI) caused by susceptible bacteria. It is effective against a broad spectrum of Gram-positive and Gram-negative pathogens, including multidrug-resistant strains. The chemical is administered intravenously, making it suitable for hospital settings where patients require intensive care for severe infections. Its broad-spectrum activity makes it a valuable option when other antibiotics are ineffective due to resistance. Eravacycline dihydrochloride is particularly useful in treating infections caused by bacteria such as Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecalis. It is often considered when first-line treatments fail or are unsuitable, providing a critical option for managing challenging infections.